tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Butcher SP et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. 1997 J. Neurosci. pmid:9278529
Vaden SL Cyclosporine and tacrolimus. 1997 Semin. Vet. Med. Surg. Small Anim. pmid:9283240
Ellouk-Achard S et al. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. 1997 Arch. Toxicol. pmid:9209689
Fletcher L Specific neuroimmunophilin ligands to treat neurodegenerative disease. 1997 Mol Med Today pmid:9449119
Lauerma AI et al. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. 1997 Skin Pharmacol. pmid:9449161
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Ciancio G et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. 1997 Clin Transplant pmid:9193850
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Cameron AM et al. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. 1997 J. Biol. Chem. pmid:9346894
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Hosoi R et al. Isoform-specific up-regulation by ouabain of Na+,K+-ATPase in cultured rat astrocytes. 1997 J. Neurochem. pmid:9349566
Guerini D Calcineurin: not just a simple protein phosphatase. 1997 Biochem. Biophys. Res. Commun. pmid:9199180
Krüger M et al. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells. 1997 Naunyn Schmiedebergs Arch. Pharmacol. pmid:9349628
Rouviere N et al. Immunosuppressor binding to the immunophilin FKBP59 affects the local structural dynamics of a surface beta-strand: time-resolved fluorescence study. 1997 Biochemistry pmid:9200682
Prokisch H et al. Impairment of calcineurin function in Neurospora crassa reveals its essential role in hyphal growth, morphology and maintenance of the apical Ca2+ gradient. 1997 Mol. Gen. Genet. pmid:9349701
Alak AM Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. 1997 Ther Drug Monit pmid:9200777
Saitoh O et al. Cyclosporine A inhibits interleukin-8 production in a human colon epithelial cell line (HT-29). 1997 J. Gastroenterol. pmid:9349985
Hebebrand D et al. Nerve xenograft transplantation. Immunosuppression with FK-506 and RS-61443. 1997 J Hand Surg Br pmid:9222906
Kageyama M et al. FK506-binding proteins regulate smooth muscle contractility by altering neurotransmitter release. 1997 Eur. J. Pharmacol. pmid:9314039
Rejto PA and Verkhivker GM Mean field analysis of FKBP12 complexes with FK506 and rapamycin: implications for a role of crystallographic water molecules in molecular recognition and specificity. 1997 Proteins pmid:9223178
Reynolds KA et al. Biosynthesis of the shikimate-derived starter unit of the immunosuppressant ascomycin: stereochemistry of the 1,4-conjugate elimination. 1997 J. Antibiot. pmid:9315087
Birnbaum AH et al. Recurrence of autoimmune hepatitis in children after liver transplantation. 1997 J. Pediatr. Gastroenterol. Nutr. pmid:9226522
Alarcón CM and Heitman J FKBP12 physically and functionally interacts with aspartokinase in Saccharomyces cerevisiae. 1997 Mol. Cell. Biol. pmid:9315655
Cardoso CM et al. Uncoupling of Ca2+ transport ATPase in muscle and blood platelets by diacylglycerol analogues and cyclosporin A antagonism. 1997 Biochem. J. pmid:9581558
Krämer BK and Schweda F Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9093272
Openshaw H Peripheral neuropathy after bone marrow transplantation. 1997 Biol. Blood Marrow Transplant. pmid:9360782
Maurer M et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. 1997 Am. J. Pathol. pmid:9094998
Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. 1997 J. Heart Lung Transplant. pmid:9361242
Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. 1997 Nat. Med. pmid:9095176
Nakai A et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. 1997 Neurobiol. Dis. pmid:9361306
Reyes J et al. Graft-versus-host disease after liver and small bowel transplantation in a child. 1997 Clin Transplant pmid:9361921
Blau CA et al. A proliferation switch for genetically modified cells. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9096348
Neu AM et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). 1997 Clin Transplant pmid:9361932
Garcia-Morales R et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 1997 J. Clin. Invest. pmid:9062371
Xenos EX et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. 1997 Clin Transplant pmid:9361949
Göthel SF et al. An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. 1997 Eur. J. Biochem. pmid:9063446
Dumont FJ FK506 enhances IL-13 production by T cells activated through CD3/CD28. 1997 Int. Arch. Allergy Immunol. pmid:9363914
Motamedi H et al. Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506. 1997 Eur. J. Biochem. pmid:9063448
Taylor PJ et al. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. 1997 Clin. Chem. pmid:9365410
Guckelberger O et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. 1997 Clin Transplant pmid:9067697
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Kloke O et al. Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells. 1997 Immunol. Lett. pmid:9373220
Eberlein-König B et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. 1997 Arch. Dermatol. Res. pmid:9373722
Rudant E et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. 1997 J Clin Pharm Ther pmid:9373812
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Huang J and Schreiber SL A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391035
Nyanguile O et al. A nonnatural transcriptional coactivator. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391036
Kageyama S et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. 1997 Acta Virol. pmid:9391652
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Alessiani M et al. [Flexibility of the surgical model of intestinal transplantation in swine]. 1997 Minerva Chir pmid:9432575
Ito E and Tanaka Y Influences of immunosuppressive agents, FK506 and cyclosporin on systemic Candida albicans infection in mice. 1997 Mycopathologia pmid:9433807
Boucek MM et al. The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report--1997. 1997 J. Heart Lung Transplant. pmid:9436131
Filler G et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. 1997 Nephrol. Dial. Transplant. pmid:9269646
Sperr WR et al. Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. 1997 Int. Arch. Allergy Immunol. pmid:9303333
Azuma H et al. Atypical Epstein-Barr virus infection during and after intermittent FK506 therapy. 1997 Acta Paediatr Jpn pmid:9141259
Izuishi K et al. Effects of an immunosuppressive agent, tacrolimus (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems in rat liver microsomes. 1997 Int. J. Biochem. Cell Biol. pmid:9304807
Tsuchida Y et al. Vascularized bone marrow allotransplantation in rats prolongs a simultaneous skin allograft. 1997 Transplant. Proc. pmid:9142252
Jonas S et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. 1997 Cancer pmid:9305716
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Tze WJ et al. Prolongation of pig islet xenograft survival in rats immunosuppressed with FK506. 1997 Diabetes Res. Clin. Pract. pmid:9306035
Soin AS et al. Complement activation during rejection in experimental intestinal transplantation. 1997 Transplant. Proc. pmid:9142282
Tanaka H et al. [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. 1997 Yakugaku Zasshi pmid:9306728
Rossi G et al. Small bowel transplantation under oral immunosuppression: experimental study in the pig. 1997 Transplant. Proc. pmid:9142285
Kamada H et al. Immunopharmacological studies on collagen-induced arthritis in dark Agouti (DA) rats. 1997 Jpn. J. Pharmacol. pmid:9307327
Spada M et al. Tacrolimus and mycophenolate mofetil in pig small bowel transplantation: different protocols and their outcome. 1997 Transplant. Proc. pmid:9142286
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Ronchetti F et al. Intestinal damage evaluation in swine allograft small bowel through hyaluronic acid quantification. 1997 Transplant. Proc. pmid:9142293
Atkison PR et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. 1997 Transplantation pmid:9311719
Velio P et al. Combined orthotopic liver-small bowel transplantation or small bowel transplantation in pigs: relations between survival, rejection, and mucosal morphometry. 1997 Transplant. Proc. pmid:9142295
Graef IA et al. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. 1997 EMBO J. pmid:9312021
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Gold BG FK506 and the role of immunophilins in nerve regeneration. 1997 Mol. Neurobiol. pmid:9457703
Mignat C Clinically significant drug interactions with new immunosuppressive agents. 1997 Drug Saf pmid:9113494
Su Y et al. Thyroid hormone induces apoptosis in primary cell cultures of tadpole intestine: cell type specificity and effects of extracellular matrix. 1997 J. Cell Biol. pmid:9396758
Bielefeldt K et al. Tacrolimus (FK506) modulates calcium release and contractility of intestinal smooth muscle. 1997 Cell Calcium pmid:9502200
Yamaguchi Y et al. Enhanced expression of cytokine-induced neutrophil chemoattractant in rat hepatic allografts during acute rejection. 1997 Hepatology pmid:9397996
Mollison KW et al. Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. 1997 J. Pharmacol. Exp. Ther. pmid:9400028
Mondragon A et al. Overexpression and purification of human calcineurin alpha from Escherichia coli and assessment of catalytic functions of residues surrounding the binuclear metal center. 1997 Biochemistry pmid:9125515
Murthy JN et al. Identification of a 37 kDa tacrolimus, sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the Jurkat T cell line. 1997 Clin. Biochem. pmid:9127694
Bowman AR et al. The role of testosterone in cyclosporine-induced osteopenia. 1997 J. Bone Miner. Res. pmid:9101372
Guérette B et al. Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1. 1997 J. Leukoc. Biol. pmid:9103242
High KP and Washburn RG Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). 1997 J. Infect. Dis. pmid:8985226
Yoshikai Y et al. Clonal expansion of superantigen-reactive T cells is resistant to FK506 in mice with AIDS. 1997 J. Virol. pmid:8985410
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Noguchi N et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. 1997 J. Biol. Chem. pmid:9013543
Ishizuka T et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. 1997 Biochem. Biophys. Res. Commun. pmid:9016789
Bagnis C et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. 1997 Am. J. Nephrol. pmid:9057948
Ivery MT and Weiler L Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex. 1997 Bioorg. Med. Chem. pmid:9061187
Prasad NV et al. Metabolism of tacrolimus (FK 506) in rat liver microsomes. Effect of rifampin and dexamethasone. 1997 Res. Commun. Mol. Pathol. Pharmacol. pmid:9178371
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110
Guérette B et al. Prevention by anti-LFA-1 of acute myoblast death following transplantation. 1997 J. Immunol. pmid:9278346